Gluten-Free Claims on Dietary Supplements: What FDA's 20 ppm Standard Demands From Your Testing Program

FDA’s gluten-free labeling rule applied to conventional foods starting in August 2014. For years afterward, a lot of supplement brands operated on the assumption that they were in a different regulatory category — different rules, different scrutiny, different risk. In August 2020, FDA closed that gap.

The rule under 21 CFR Part 101.91 now covers dietary supplements fully and without exception. If your label says “gluten-free,” “no gluten,” “free of gluten,” or “without gluten,” you’re on the hook for demonstrating that gluten levels stay below 20 parts per million — not once, but consistently, batch to batch.

The problem is that testing a supplement matrix for gluten at the 5–20 ppm range is genuinely harder than testing a slice of bread. Most supplement brands don’t discover this until they’re already mid-audit or mid-recall.

Why the 20 ppm Threshold Exists — and What It Means for Your Label

The 20 ppm ceiling wasn’t chosen arbitrarily. It traces back to clinical research — including work published by Catassi and colleagues — establishing that daily gluten consumption above approximately 50 mg reliably causes measurable intestinal damage in people with celiac disease. Working backward through plausible serving sizes, 20 ppm provides a meaningful safety margin for the roughly 3.3 million Americans (about 1% of the U.S. population) who live with celiac disease. An additional 6% or more may experience non-celiac gluten sensitivity — a group that also relies on label accuracy, even though the science on their specific tolerance thresholds is still evolving.

For supplement manufacturers, the compliance picture is straightforward: any claim that communicates the absence of gluten triggers the 20 ppm standard. What’s less obvious is the enforcement pathway. FDA investigators reviewing supplement facilities under 21 CFR Part 111 — the cGMP regulations for dietary supplements — can and do look at whether label claims are substantiated. An unsubstantiated “gluten-free” claim, meaning one without documented testing or ingredient sourcing controls, can be cited as a labeling violation under 21 CFR Part 101.91, regardless of what the product actually contains.

We’ve reviewed situations where companies received FDA Warning Letters citing exactly this gap: the claim was on the label, but there was no testing data, no supplier documentation, and no cleaning validation for shared equipment. The product might have been perfectly gluten-free. There was just no way to prove it.

How Labs Actually Test for Gluten in Supplement Products

The two primary methods for gluten detection are ELISA (enzyme-linked immunosorbent assay) and PCR (polymerase chain reaction). Each has a legitimate role, and each has real limitations when applied to supplement matrices specifically.

ELISA-based methods are the most widely accepted for regulatory compliance testing. The R5 competitive ELISA, validated under AOAC Official Method 2012.01, is specifically designed for products containing hydrolyzed or fermented gluten sources — a critical distinction, because many supplement ingredients undergo processing steps that partially break down gluten proteins. The R5 sandwich ELISA, while highly sensitive to intact gliadin fractions, can underreport in heavily processed matrices because the antibody requires a minimum peptide length to bind effectively. A lab that doesn’t understand this distinction can hand you a result below 20 ppm that doesn’t actually mean what you think it means.

PCR methods detect wheat, barley, or rye DNA, making them useful for ingredient identity confirmation. But they can’t distinguish between intact, immunoreactive gluten and fully denatured protein fragments that pose no celiac risk. For compliance purposes against the 20 ppm standard, PCR alone is not a defensible primary method.

Detection limits matter more here than most brands realize. ISO 17025 accredited labs with properly validated ELISA methods can reliably quantify gluten down to 5 ppm — giving you a 4x margin of safety below FDA’s limit. Labs operating without fit-for-purpose, validated methods may have effective detection limits of 10–15 ppm, which collapses that margin considerably and creates real exposure if results cluster near the threshold.

Why Supplement Matrices Make Gluten Testing Harder Than It Looks

Testing a wheat cracker for gluten is straightforward. Testing a multi-ingredient supplement — particularly one containing botanical extracts, high-starch excipients, or fermentation-derived ingredients — introduces complications that a food safety testing laboratory encounters regularly but that brands frequently underestimate.

Matrix interference is the most common issue we see. Certain supplement excipients, including tapioca maltodextrin, rice starch, and some amorphous silica forms, can interfere with ELISA antibody-antigen binding. The result can be a false positive (the matrix signals as gluten-containing when it isn’t) or signal suppression (actual gluten goes undetected). The appropriate solution is a matrix-specific spike recovery study: the lab spikes a known concentration of gluten standard into your actual product matrix and measures recovery. Acceptable recovery typically falls between 80% and 120%. Below 80%, the result requires correction or the method requires re-optimization for your formulation.

Botanical cross-reactivity is underappreciated and underreported in most lab reports. A handful of commonly used botanicals — including certain rice-derived compounds and some legume and grain-based extracts — can produce false-positive signals with anti-gliadin antibodies used in sandwich ELISA assays. This doesn’t mean those botanicals contain gluten; it means the antibody is reacting to structurally similar proteins. An experienced analyst will know which ingredients in your formulation carry this risk and will select an appropriate assay — and flag the issue before reporting.

Oats deserve specific attention. Even oats grown and harvested under certified gluten-free protocols require verification, because ELISA cross-reactivity with avenins — oat proteins that share structural features with gliadin — is well-documented in the literature. Some celiac patients react to avenins at concentrations well below the 20 ppm wheat-gluten threshold. If your supplement contains oat fiber, oat bran, or oat-derived extract, this belongs in your specification documentation and should be addressed explicitly in your label claim substantiation file.

What FDA Expects When Your Claim Gets Audited

A passing gluten test result from a third-party lab is good evidence. It is not, by itself, a complete substantiation.

Under 21 CFR Part 101.91(b)(3), a product is misbranded if it bears a gluten-free claim and fails to meet the standard — but FDA’s broader inspection authority means that even brands with passing test data can face citations if their manufacturing controls can’t credibly support the claim. In practice, the documentation stack that holds up under a real FDA audit includes: ingredient specifications documenting gluten-free sourcing for every raw material, supplier COAs with gluten testing data, cleaning validation records for shared equipment, and finished product testing results from an accredited laboratory.

ISO 17025 accreditation of the testing lab specifically matters here because it demonstrates that the lab operates under documented, audited quality management systems — not just capable equipment and experienced staff. When FDA reviews your testing records, results from an accredited lab carry substantially more evidentiary weight than results from a non-accredited provider.

Companies that rely on finished product testing alone, without upstream ingredient documentation, are one supply chain disruption away from a label claim they can no longer defend.

Building a Testing Program That Actually Holds Up

The substantiation approach we walk supplement brands through involves four layers, applied in sequence rather than all at once.

Start upstream with supplier qualification. Request documentation showing that each ingredient has been tested for gluten at the supplier level and that manufacturing facilities have meaningful segregation controls. “Tested at source” data reduces — but does not eliminate — your finished product testing burden. It also gives you a defensible record if a supplier switches a production line without notifying you.

Validate your testing method against your actual matrix. Don’t accept a generic food ELISA result as sufficient. Ask your food safety testing laboratory whether they’ve conducted spike recovery studies on your specific product type. If they haven’t, ask them to before you finalize your testing protocol. This validation step is the single most common gap we see in supplement gluten testing programs.

Establish a testing frequency that matches your risk profile. Products containing multiple botanical ingredients, manufactured on shared equipment, or specifically marketed to a celiac audience warrant every-lot finished product testing. A single-ingredient supplement manufactured on a dedicated gluten-free line may be defensible with periodic verification testing, provided your supplier qualification documentation is current and complete.

Retain your records in accessible form. FDA’s cGMP regulations at 21 CFR Part 111.605 require that records be maintained for at least one year beyond the shelf life date or two years beyond the distribution date, whichever is longer. Testing data that ages out of your document management system is testing data you cannot use when you need it most — and under FDA inspection, “we no longer have those records” is not a position you want to be in.

The 2020 extension of the gluten-free labeling rule to supplements wasn’t a surprise to manufacturers tracking FDA’s regulatory posture. But the testing requirements it creates — matrix-matched ELISA methods, spike recovery validation, ISO 17025 accreditation — require a food safety laboratory partner that understands supplement product forms specifically, not just conventional food matrices. The method that works perfectly for a granola bar may give you a result you can’t defend when applied to a botanical capsule.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• FDA Audit Readiness and Labeling Compliance for Regulated Products — Aurora TIC covers 21 CFR compliance strategy, FDA audit preparation, and regulatory documentation programs for supplement and food brands.
• Raw Material Gluten Specification and Supplier COA Verification — Ayah Labs specializes in raw material qualification testing and COA verification for ingredient suppliers serving the dietary supplement industry.